Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.45 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175370 | 0.89 | ATM (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL4929205 | 0.89 | ATM (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL4937101 | 0.89 | ATM (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL2878097 | 0.87 | ADORA3 (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL173832 | 0.87 | ATM (0.51) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL255820 | 0.84 | ADORA3 (0.50) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL2883538 | 0.84 | PDE5A (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL19126595 | 0.84 | ADORA3 (0.49) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL19126771 | 0.84 | ADORA3 (0.51) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL18672347 | 0.83 | PDE5A (0.51) | PDE5AKMT2AMEN1GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017121693-A1 | SUBSTITUTED THIAZOLE AND THIADIAZOLE AMIDES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121700-A1 | 1,3-DISUBSTITUTED 1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AND USE THEREOF AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121700-A1 | 1,3-DISUBSTITUTED 1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AND USE THEREOF AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-20 | — | — | WO | disclosed |
| EP-2611802-B1 | BICYCLIC AZA-HETEROCYCLES AND THEIR USE | BAYER IP GMBH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-9096592-B2 | Bicyclic aza heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| EP-2611802-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| EP-2013205-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | Bayer HealthCare AG (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
| US-6451805-B1 | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | AADAC, PAICS, TPMT | ATM 3549/4885ADORA3 814/4885KCNH2 1555/4885 |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | AADAC, CYP11B2, PC | ATM 1031/4885ADORA3 492/4885KCNH2 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.